Cantor Fitzgerald Initiates Coverage On Belite Bio with Overweight Rating, Announces Price Target of $43
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Jennifer Kim has initiated coverage on Belite Bio (NASDAQ:BLTE) with an Overweight rating and a price target of $43.
July 28, 2023 | 11:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Belite Bio has been given an Overweight rating by Cantor Fitzgerald, with a price target of $43.
The Overweight rating from Cantor Fitzgerald indicates a positive outlook for Belite Bio. The price target of $43 suggests significant upside potential from current levels. This could lead to increased investor interest and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100